

21 May 2025

**Scancell Holdings plc**  
("Scancell" or the "Company")

**Director Dealing**

Scancell (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, announces that Vulpes Testudo Fund, a fund closely associated with Martin Diggle, Non-Executive Director, has purchased 497,764 ordinary shares of 0.9p each ('Ordinary Shares') in the Company between 15 May 2025 and 20 May 2025 at a price of 9 pence per share. Following the purchase, Vulpes Life Science Fund and Vulpes Testudo Fund together hold 130,884,801 ordinary shares representing 12.62% of the company.

**NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING  
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM**

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>		
a)	Name	Vulpes Testudo Fund	
<b>2</b>	<b>Reason for the notification</b>		
a)	Position/status	Fund closely associated with Martin Diggle, Non-Executive Director	
b)	Initial notification/Amendment	Initial notification	
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	Scancell Holdings plc	
b)	LEI	2138008RXEG856SNP666	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.9 pence each	
b)	Identification Code	GB00B63D3314	
c)	Nature of the transaction	Purchase of Ordinary Shares	
d)	Price(s) and volume(s)	1.	9 pence
		2.	9 pence
		3.	9 pence
e)	Aggregated information - Aggregated volume - Price	497,764 Ordinary Shares 9 pence per Ordinary Share	
f)	Date of the transaction	1.	15 May 2025
		2.	16 May 2025
		3.	20 May 2025
g)	Place of the transaction	London Stock Exchange, AIM	

**For further information, please contact:**

**Scancell Holdings plc**

Phil L'Huillier, CEO

Sath Nirmalanathan, CFO

Dr Jean-Michel Cosséry, Non-Executive Chairman

+44 (0) 20 3709 5700

**Panmure Liberum** (Nominated Adviser and Joint Broker)

Emma Earl, Will Goode, Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0) 20 7886 2500

**WG Partners LLP (Joint Broker)**

David Wilson, Claes Spang

+44 (0) 20 3705 9330

**ICR Healthcare**

Mary-Jane Elliott, Stephanie Cuthbert, Chris Welsh

+44 (0) 20 3709 5700

[scancell@consilium-comms.com](mailto:scancell@consilium-comms.com)

**About Scancell**

Scancell (LSE:SCLP) develops immunotherapies for a Cancer-free future by enhancing long-lasting tumour specific immunity. As a clinical stage biotechnology company with deep roots in cancer immunology and translational research, Scancell develops tumour targeted off-the-shelf vaccines, with highly favourable safety and durable systemic immune responses. Scancell's lead product, iSCIB1+, a DNA vaccine, is currently showing strong promise on top of checkpoint therapies in a multi-arm phase 2 study in first-line melanoma. The second vaccine, Modi-1, is being investigated in a phase 2 study in a broad range of solid tumours. Scancell is also developing a pipeline of high affinity antibodies targeting tumour specific glycans using its proprietary platforms. Two of these antibodies are now being developed in major biopharma partnerships, and a further two antibodies targeting lung and epithelial cancers are actively being developed in-house.

<https://www.scancell.co.uk>